A Pooled Analysis of the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to EValuate the Safety and Efficacy of Iclaprim Versus Vancomycin for trEatment of Acute Bacterial Skin and Skin Structure Infections

Up to 1.8% of all hospitalizations are for an acute bacterial skin and skin structure infections (ABSSSI) [1]. Often these serious skin infections require intravenous antibiotics, hospitalization, and/or surgical intervention [2,3]. The majority of ABSSSI are caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible S. aureus (MSSA), and beta-hemolytic streptococci [3,4]. Although many antibiotics are available to treat ABSSSI, only a few are available for ABSSSI caused by multidrug resistant (MDR) bacteria, and some of these are limited by safety, tolerability and dosing issues [5], the need for monitoring plasma concentrations, and/or inconvenient dosage regimens [6].

Source: International Journal of Antimicrobial Agents - May 18, 2018 Category: Drugs & Pharmacology Authors: David B Huang, G. Ralph Corey, Thomas L Holland, Thomas Lodise, William O'Riordan, Mark H Wilcox, Thomas M File, Matthew Dryden, Barbara Balser, Eve Desplats, Antoni Torres Source Type: research